DEX containing MHC I, MHC II, CD86, and HSP70-90 chaperones are capable of triggering the activation of CD4+ and CD8+ T-cell activation (16, 46), thereby inducing more effective antitumor immunity and addressing the poor immunogenicity of tumor antigens. Here, CD4 is linked to neoplasm.